NI201800061A - Enlazadores de pd1 y/o lag3 - Google Patents
Enlazadores de pd1 y/o lag3Info
- Publication number
- NI201800061A NI201800061A NI201800061A NI201800061A NI201800061A NI 201800061 A NI201800061 A NI 201800061A NI 201800061 A NI201800061 A NI 201800061A NI 201800061 A NI201800061 A NI 201800061A NI 201800061 A NI201800061 A NI 201800061A
- Authority
- NI
- Nicaragua
- Prior art keywords
- lag3
- molecules
- links
- treating
- isvd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Photoreceptors In Electrophotography (AREA)
- Ceramic Products (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona moléculas, tales como ISVD y Nanocuerpos, que se unen a PD1 y LAG3 y opcionalmente a albúmina de sérica humana. Estas moléculas se han diseñado con el fin de reducir la incidencia de la unión por anticuerpos preexistentes en el cuerpo de un sujeto administrado con una molécula de este tipo. Se proporcionan procedimientos para incrementar la respuesta inmunitaria, tratar cáncer y/o tratar una enfermedad infecciosa con dichas moléculas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562257009P | 2015-11-18 | 2015-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201800061A true NI201800061A (es) | 2018-07-24 |
Family
ID=57472067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201800061A NI201800061A (es) | 2015-11-18 | 2018-05-15 | Enlazadores de pd1 y/o lag3 |
Country Status (31)
Country | Link |
---|---|
US (5) | US10323090B2 (es) |
EP (1) | EP3377531A2 (es) |
JP (3) | JP6817302B2 (es) |
KR (3) | KR102194188B1 (es) |
CN (1) | CN108473585B (es) |
AR (1) | AR106754A1 (es) |
AU (3) | AU2016355570B2 (es) |
BR (1) | BR112018010084A2 (es) |
CA (3) | CA3131983C (es) |
CL (3) | CL2018001327A1 (es) |
CO (1) | CO2018005126A2 (es) |
CR (1) | CR20180278A (es) |
DO (2) | DOP2018000126A (es) |
EA (1) | EA201891165A1 (es) |
EC (1) | ECSP18045468A (es) |
GE (1) | GEP20217220B (es) |
HK (1) | HK1254951A1 (es) |
IL (2) | IL300122A (es) |
JO (1) | JO3744B1 (es) |
MA (1) | MA43260A (es) |
MX (2) | MX2018006245A (es) |
MY (1) | MY189018A (es) |
NI (1) | NI201800061A (es) |
PE (1) | PE20181532A1 (es) |
PH (1) | PH12018501080A1 (es) |
SG (2) | SG11201804178YA (es) |
SV (1) | SV2018005694A (es) |
TN (1) | TN2018000172A1 (es) |
TW (2) | TW202216787A (es) |
UA (1) | UA121914C2 (es) |
WO (1) | WO2017087589A2 (es) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
KR20220114104A (ko) | 2011-06-23 | 2022-08-17 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
MX2016014926A (es) | 2014-05-16 | 2017-05-09 | Ablynx Nv | Dominios variables de inmunoglobulina mejorados. |
MX2018000621A (es) | 2015-07-13 | 2018-05-11 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
CA3004900C (en) | 2015-11-18 | 2021-08-10 | Merck Sharp & Dohme Corp. | Ctla4 binders |
US11332519B2 (en) * | 2015-11-18 | 2022-05-17 | Ablynx N.V. | Serum albumin binders |
KR102194188B1 (ko) * | 2015-11-18 | 2020-12-24 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
JP7085708B2 (ja) | 2016-06-20 | 2022-06-17 | エフ-スター セラピューティクス リミテッド | Lag-3結合要素 |
LT3472207T (lt) | 2016-06-20 | 2021-05-10 | F-Star Delta Limited | Surišančios molekulės, kurios suriša pd-l1 ir lag-3 |
CN109475603B (zh) | 2016-06-20 | 2023-06-13 | 科马布有限公司 | 抗pd-l1抗体 |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
WO2018071500A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
WO2018127710A1 (en) | 2017-01-06 | 2018-07-12 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
US20200079850A1 (en) * | 2017-05-24 | 2020-03-12 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
CA3065304A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
KR20200010501A (ko) | 2017-05-30 | 2020-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 양성 종양의 치료 |
EP4245375A3 (en) | 2017-05-30 | 2023-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
JP2020525533A (ja) * | 2017-07-06 | 2020-08-27 | メルス ナムローゼ フェンノートシャップ | 細胞により発現される生物学的活性を調節する抗体 |
SG11202004426SA (en) * | 2017-11-17 | 2020-06-29 | Merck Sharp & Dohme | Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof |
TW201930355A (zh) | 2017-12-19 | 2019-08-01 | 英商F星貝塔有限公司 | 結合物件(三) |
EP3732203A4 (en) * | 2017-12-28 | 2021-12-15 | Nanjing Legend Biotech Co., Ltd. | ANTIBODIES AND VARIANTS THEREOF AGAINST PD-L1 |
US11713353B2 (en) * | 2018-01-15 | 2023-08-01 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-1 |
US11655295B2 (en) | 2018-01-18 | 2023-05-23 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-LAG-3 antibody and use thereof |
EP3746480A1 (en) * | 2018-01-31 | 2020-12-09 | F. Hoffmann-La Roche AG | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
GB201802573D0 (en) * | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
JP7438180B2 (ja) * | 2018-03-20 | 2024-02-26 | ウーシー バイオロジクス アイルランド リミテッド | 新規抗lag-3抗体ポリペプチド |
US20210115138A1 (en) * | 2018-03-20 | 2021-04-22 | WuXi Biologics Ireland Limited | Novel bispecific pd-1/lag-3 antibody molecules |
US20210061912A1 (en) * | 2018-03-20 | 2021-03-04 | WuXi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
KR20200138720A (ko) * | 2018-03-30 | 2020-12-10 | 난징 레전드 바이오테크 씨오., 엘티디. | Lag-3에 대한 단일-도메인 항체 및 이의 용도 |
JP7368453B2 (ja) * | 2018-05-03 | 2023-10-24 | シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド | Pd-1およびlag-3に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質 |
CN112236455B (zh) * | 2018-05-17 | 2023-05-16 | 南京维立志博生物科技有限公司 | 结合pd-1的抗体及其用途 |
US20210238287A1 (en) | 2018-07-26 | 2021-08-05 | Bristol-Myers Squibb Company | LAG-3 Combination Therapy for the Treatment of Cancer |
CA3114272A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Degradable hyaluronic acid hydrogels |
CN113286611A (zh) | 2018-10-19 | 2021-08-20 | 百时美施贵宝公司 | 用于黑色素瘤的组合疗法 |
US20230051872A1 (en) * | 2019-03-22 | 2023-02-16 | Reflexion Pharmaceuticals, Inc. | Multivalent D-Peptidic Compounds for Target Proteins |
EP3715376A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of myasthenia gravis |
US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
EP3715375A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of pre-eclampsia |
EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
WO2020216348A1 (en) * | 2019-04-26 | 2020-10-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against pd-1 and lag-3 |
CN110179977A (zh) * | 2019-05-22 | 2019-08-30 | 华中科技大学同济医学院附属同济医院 | 用于治疗黑色素瘤、肺癌或结直肠癌的组合药物制剂 |
CN114174537A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
WO2020263717A1 (en) * | 2019-06-26 | 2020-12-30 | Merck Sharp & Dohme Corp. | Process for separating antigen-binding polypeptide monomers comprising one or more immunoglobulin single variable domains from aggregates |
WO2021008559A1 (en) * | 2019-07-16 | 2021-01-21 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against pd-1 and lag-3 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
CN110981958B (zh) * | 2019-08-23 | 2020-10-20 | 四川大学华西医院 | 一种pd-l1抗体 |
KR20220066334A (ko) | 2019-09-22 | 2022-05-24 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 길항제 요법에 대한 정량적 공간 프로파일링 |
WO2021057866A1 (zh) * | 2019-09-26 | 2021-04-01 | 苏州克睿基因生物科技有限公司 | 一种单域抗体及包含抗体结构的嵌合抗原受体 |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
JP2022553851A (ja) | 2019-11-08 | 2022-12-26 | ブリストル-マイヤーズ スクイブ カンパニー | 黒色腫の処置のためのlag-3アンタゴニスト |
US20230087600A1 (en) | 2020-02-06 | 2023-03-23 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
CN113461824A (zh) * | 2020-03-31 | 2021-10-01 | 普米斯生物技术(珠海)有限公司 | 一种构建多特异性抗体的平台 |
JP2023532768A (ja) | 2020-07-07 | 2023-07-31 | バイオエヌテック エスエー | Hpv陽性癌の治療用rna |
WO2022047189A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
US20230381334A1 (en) | 2020-09-23 | 2023-11-30 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
WO2022109987A1 (en) * | 2020-11-27 | 2022-06-02 | Shanghai Benemae Pharmaceutical Corporation | Novel anti-lag3 antibodies and methods of making and using the same |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
EP4267172A1 (en) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
MX2023007734A (es) | 2020-12-28 | 2023-08-21 | Bristol Myers Squibb Co | Composiciones de anticuerpos y metodos de uso de las mismas. |
WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
EP4337694A1 (en) | 2021-05-12 | 2024-03-20 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
CN113307874B (zh) * | 2021-05-31 | 2022-05-27 | 广州爱思迈生物医药科技有限公司 | 一种抗lag3的抗体及其应用 |
WO2022266235A1 (en) * | 2021-06-15 | 2022-12-22 | The Trustees Of Columbia University In The City Of New York | Nanobodies against sars-cov-2 for detection of sars-cov-2, and diagnosis, treatment and prevention of infection and disease caused by sars-cov-2 |
KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
CN117999077A (zh) | 2021-07-28 | 2024-05-07 | 株式会社蒂奥姆生物 | 用于预防或***的药物组合物及其用途 |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
CN115028726B (zh) * | 2022-03-31 | 2024-01-09 | 浙江特瑞思药业股份有限公司 | 一种抗pd-1纳米抗体及其应用 |
CN114984207B (zh) * | 2022-05-09 | 2024-01-26 | 浙江特瑞思药业股份有限公司 | 一种抗pd-1纳米抗体制剂 |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024017281A1 (zh) * | 2022-07-20 | 2024-01-25 | 明慧医药(杭州)有限公司 | 多特异性抗体及其用途 |
WO2024072893A1 (en) * | 2022-09-28 | 2024-04-04 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
CA2145769A1 (en) | 1992-09-29 | 1994-04-14 | Gerald D. Fischbach | Trophic factor having ion channel-inducing activity in neuronal cells |
US6824779B1 (en) | 1993-07-26 | 2004-11-30 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting the interaction of B7-2 with its natural ligand |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US20020006403A1 (en) | 1999-12-14 | 2002-01-17 | Xue-Zhong Yu | CD28-specific antibody compositions for use in methods of immunosuppression |
US7795002B2 (en) | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
AU2001296962A1 (en) | 2000-09-29 | 2002-04-08 | Schering Corporation | Pegylated interleukin-10 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
DE60142794D1 (de) | 2000-12-26 | 2010-09-23 | Inst Nat Sante Rech Med | Antikörper gegen cd28 |
AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US20040083084A1 (en) | 2002-10-24 | 2004-04-29 | Mike West | Binary prediction tree modeling with many predictors |
EP2390268B1 (en) | 2002-11-08 | 2017-11-01 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
PT1687338E (pt) | 2003-11-07 | 2011-01-20 | Ablynx Nv | Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações |
PE20090047A1 (es) | 2003-11-10 | 2009-01-26 | Schering Corp | Anticuerpo recombinante humanizado anti-interleuquina 10 |
WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
MX363423B (es) | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
US20080267949A1 (en) | 2006-12-05 | 2008-10-30 | Ablynx N.V. | Peptides capable of binding to serum proteins |
WO2008071447A2 (en) * | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
WO2012130874A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
US20100143336A1 (en) | 2007-04-26 | 2010-06-10 | Opsona Therapeutics Limited | Toll-like receptor binding epitope and compositions for binding thereto |
ES2663512T3 (es) | 2007-05-24 | 2018-04-13 | Ablynx N.V. | Secuencias de aminoácidos dirigidas contra RANK-L y polipéptidos que comprenden las mismas para el tratamiento de enfermedades y trastornos óseos |
CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
BRPI0911984A2 (pt) | 2008-05-16 | 2016-09-20 | Ablynx Nv | sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos |
AR073459A1 (es) * | 2008-07-18 | 2010-11-10 | Domantis Ltd | Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso |
AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
JP2012510429A (ja) | 2008-08-25 | 2012-05-10 | アンプリミューン、インコーポレーテッド | Pd−1アンタゴニストおよびその使用方法 |
WO2011006915A2 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
EP2591001B1 (en) | 2010-07-09 | 2021-11-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to cd27 |
US10076245B2 (en) | 2011-06-22 | 2018-09-18 | Canon Kabushiki Kaisha | Specimen information acquisition apparatus and specimen information acquisition method |
PL2723771T3 (pl) | 2011-06-23 | 2020-04-30 | Ablynx Nv | Białka wiążące albuminy surowicy |
KR20220114104A (ko) | 2011-06-23 | 2022-08-17 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
CA2845029A1 (en) | 2011-08-17 | 2013-02-21 | Glaxo Group Limited | Modified proteins and peptides |
WO2013066765A1 (en) | 2011-11-01 | 2013-05-10 | Merck Sharp & Dohme Corp. | Mutation of tup1 in glycoengineered yeast |
AU2013201422B2 (en) | 2012-01-23 | 2015-04-09 | Ablynx Nv | Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
BR112015003851A2 (pt) * | 2012-08-21 | 2017-08-08 | Glaxo Group Ltd | composições compreendendo um domínio variável único e mesilato de camostato (cm) |
EP2895510A2 (en) | 2012-09-13 | 2015-07-22 | Novartis AG | Single domain antibody with c-terminal modification |
CN104902867A (zh) | 2012-12-11 | 2015-09-09 | 积水精细化工美国有限公司 | 用于个人护理的聚乙烯醇共聚物 |
WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
HUE062317T2 (hu) | 2013-09-20 | 2023-10-28 | Bristol Myers Squibb Co | Anti-LAG-3 antitestek és anti-PD-1 antitestek kombinációja tumorok kezeléséhez |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
PT3049439T (pt) * | 2013-09-26 | 2020-03-31 | Ablynx Nv | Nanocorpos biespecíficos |
MX2016005915A (es) | 2013-11-11 | 2016-12-16 | Armo Biosciences Inc | Metodos de uso de interleucina-10 para tratar enfermedades y trastornos. |
SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CU24481B1 (es) * | 2014-03-14 | 2020-03-04 | Immutep Sas | Moléculas de anticuerpo que se unen a lag-3 |
BR122018009619B1 (pt) * | 2014-05-16 | 2024-01-02 | Ablynx N.V | Domínios variáveis de imunoglobulina aperfeiçoados |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
PT3168262T (pt) | 2014-07-08 | 2019-12-09 | Techno Umg Co Ltd | Composição de resina termoplástica e artigo moldado da mesma |
HUE059131T2 (hu) | 2014-08-11 | 2022-10-28 | Acerta Pharma Bv | BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja |
SG11201701070WA (en) | 2014-08-12 | 2017-03-30 | Alligator Bioscience Ab | Combination therapies with anti cd40 antibodies |
MA40475A (fr) | 2014-08-19 | 2017-06-28 | Fayadat Dilman Laurence | Anticorps anti-tigit |
CN113577264A (zh) | 2015-04-17 | 2021-11-02 | 百时美施贵宝公司 | 包含抗pd-1抗体和另外的抗体的组合的组合物 |
JP6840127B2 (ja) | 2015-07-29 | 2021-03-10 | ノバルティス アーゲー | がんの治療における抗pd−1抗体および抗m−csf抗体の併用 |
US20180177872A1 (en) | 2015-07-29 | 2018-06-28 | Yong Jia | Combination of PD-1 antagonist with an EGFR inhibitor |
KR102055396B1 (ko) | 2015-08-11 | 2019-12-12 | 우시 바이올로직스 (케이만) 인코포레이티드 | 신규한 항-pd-1 항체 |
KR102434314B1 (ko) | 2015-09-01 | 2022-08-19 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
KR20180054824A (ko) | 2015-09-29 | 2018-05-24 | 셀진 코포레이션 | Pd-1 결합 단백질 및 이의 사용 방법 |
CR20180161A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Anticuerpos biespecíficos para pd1 y tim3 |
EP3356404B1 (en) | 2015-10-02 | 2021-08-18 | F. Hoffmann-La Roche AG | Anti-pd1 antibodies and methods of use |
CA3004900C (en) | 2015-11-18 | 2021-08-10 | Merck Sharp & Dohme Corp. | Ctla4 binders |
WO2017087587A1 (en) | 2015-11-18 | 2017-05-26 | Merck Sharp & Dohme Corp. | PD1/CTLA4 Binders |
KR102194188B1 (ko) * | 2015-11-18 | 2020-12-24 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
LT3383425T (lt) | 2015-12-04 | 2020-10-12 | Boehringer Ingelheim International Gmbh | Biparatopiniai polipeptidai, veikiantys antagonistiškai wnt signaliniam keliui vėžinėse ląstelėse |
WO2017106061A1 (en) | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
DK3458478T3 (da) | 2016-05-18 | 2021-03-22 | Boehringer Ingelheim Int | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling |
TW201803598A (zh) | 2016-06-30 | 2018-02-01 | 南特細胞公司 | Nant癌症疫苗 |
RU2656181C1 (ru) | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
BR112019004995A2 (pt) | 2016-09-14 | 2019-06-04 | Beijing hanmi pharm co ltd | anticorpo que se liga especificamente a pd-1 e fragmento funcional do mesmo |
MX2019002946A (es) | 2016-09-14 | 2019-09-26 | Abbvie Biotherapeutics Inc | Anticuerpos anti-pd-1 y sus usos. |
US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
BR112019019821A2 (pt) | 2017-04-05 | 2020-04-22 | Hoffmann La Roche | anticorpo biespecífico, polinucleotídeo, célula hospedeira procariótica ou eucariótica, métodos de produção do anticorpo biespecífico, de tratamento de um indivíduo que tem câncer ou uma infecção viral crônica e de inibição do crescimento de células de tumor, composição farmacêutica e uso do anticorpo biespecífico |
-
2016
- 2016-11-17 KR KR1020187016800A patent/KR102194188B1/ko active IP Right Grant
- 2016-11-17 SG SG11201804178YA patent/SG11201804178YA/en unknown
- 2016-11-17 KR KR1020207036090A patent/KR102317574B1/ko active IP Right Grant
- 2016-11-17 CA CA3131983A patent/CA3131983C/en active Active
- 2016-11-17 EA EA201891165A patent/EA201891165A1/ru unknown
- 2016-11-17 MY MYPI2018000773A patent/MY189018A/en unknown
- 2016-11-17 US US15/353,919 patent/US10323090B2/en active Active
- 2016-11-17 IL IL300122A patent/IL300122A/en unknown
- 2016-11-17 MA MA043260A patent/MA43260A/fr unknown
- 2016-11-17 WO PCT/US2016/062394 patent/WO2017087589A2/en active Application Filing
- 2016-11-17 JP JP2018525608A patent/JP6817302B2/ja active Active
- 2016-11-17 SG SG10201911035QA patent/SG10201911035QA/en unknown
- 2016-11-17 CA CA3132021A patent/CA3132021C/en active Active
- 2016-11-17 AU AU2016355570A patent/AU2016355570B2/en active Active
- 2016-11-17 UA UAA201806765A patent/UA121914C2/uk unknown
- 2016-11-17 MX MX2018006245A patent/MX2018006245A/es unknown
- 2016-11-17 CR CR20180278A patent/CR20180278A/es unknown
- 2016-11-17 TW TW111102788A patent/TW202216787A/zh unknown
- 2016-11-17 TN TNP/2018/000172A patent/TN2018000172A1/en unknown
- 2016-11-17 CA CA3004748A patent/CA3004748C/en active Active
- 2016-11-17 BR BR112018010084A patent/BR112018010084A2/pt active Search and Examination
- 2016-11-17 TW TW105137705A patent/TWI754621B/zh active
- 2016-11-17 KR KR1020197028947A patent/KR102220275B1/ko active IP Right Grant
- 2016-11-17 EP EP16805655.4A patent/EP3377531A2/en active Pending
- 2016-11-17 PE PE2018000983A patent/PE20181532A1/es unknown
- 2016-11-17 GE GEAP201614812A patent/GEP20217220B/en unknown
- 2016-11-17 JO JOP/2016/0244A patent/JO3744B1/ar active
- 2016-11-17 CN CN201680079323.1A patent/CN108473585B/zh active Active
- 2016-11-18 AR ARP160103543A patent/AR106754A1/es unknown
-
2018
- 2018-05-08 IL IL259224A patent/IL259224B2/en unknown
- 2018-05-15 CO CONC2018/0005126A patent/CO2018005126A2/es unknown
- 2018-05-15 NI NI201800061A patent/NI201800061A/es unknown
- 2018-05-15 SV SV2018005694A patent/SV2018005694A/es unknown
- 2018-05-17 CL CL2018001327A patent/CL2018001327A1/es unknown
- 2018-05-18 DO DO2018000126A patent/DOP2018000126A/es unknown
- 2018-05-18 MX MX2023001356A patent/MX2023001356A/es unknown
- 2018-05-18 PH PH12018501080A patent/PH12018501080A1/en unknown
- 2018-06-14 EC ECIEPI201845468A patent/ECSP18045468A/es unknown
- 2018-11-02 HK HK18114055.3A patent/HK1254951A1/zh unknown
-
2019
- 2019-05-17 US US16/415,455 patent/US11168135B2/en active Active
- 2019-05-17 US US16/415,530 patent/US11155619B2/en active Active
- 2019-05-17 US US16/415,496 patent/US11168136B2/en active Active
- 2019-09-27 JP JP2019176483A patent/JP6845905B2/ja active Active
-
2020
- 2020-03-27 AU AU2020202177A patent/AU2020202177B2/en active Active
- 2020-03-30 AU AU2020202238A patent/AU2020202238B2/en active Active
- 2020-09-29 CL CL2020002521A patent/CL2020002521A1/es unknown
- 2020-09-30 CL CL2020002531A patent/CL2020002531A1/es unknown
- 2020-12-17 JP JP2020209140A patent/JP7184866B2/ja active Active
-
2021
- 2021-01-08 DO DO2021000005A patent/DOP2021000005A/es unknown
- 2021-10-08 US US17/497,597 patent/US20220041727A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201800061A (es) | Enlazadores de pd1 y/o lag3 | |
NI201800062A (es) | Enlazadores de ctla4 | |
CL2017001154A1 (es) | Moléculas de unión específicas para cd73 y usos de las mismas | |
BR112018074453A2 (pt) | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral | |
CU24427B1 (es) | Moléculas de anticuerpo que se unen a tim-3 | |
CO2018009995A2 (es) | Proteínas de unión y métodos de uso de las mismas | |
CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
UY36859A (es) | Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas | |
CR20170079A (es) | Agentes de unión a cd123 y usos de estos | |
BR112017002646A2 (pt) | proteínas de fusão da imunoglobulina sirp-alfa | |
UY35399A (es) | Conjugados de fármacos con anticuerpos | |
BR112016022841A2 (pt) | cadeia j modificada | |
CU20170012A7 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
CO2019003759A2 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos | |
AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
DK3144676T3 (da) | Kit omfattende antistof der specifikt binder til komplementfaktor b protein og antistof der specifikt binder til kulhydratantigen 19-9 protein til diagnosticering af cancer i bugspytkirtlen | |
AR104413A1 (es) | Anticuerpo de igf-1r y su utilización para diagnosticar cáncer | |
BR112017022635A2 (pt) | anticorpo de igf-1r e seu uso para diagnóstico de câncer |